Amarin CorpAMRN
About: Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Employees: 275
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,175% more call options, than puts
Call options by funds: $153K | Put options by funds: $12K
1,001% more capital invested
Capital invested by funds: $34.4M [Q4 2024] → $379M (+$344M) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.9% less ownership
Funds ownership: 17.23% [Q4 2024] → 16.33% (-0.9%) [Q1 2025]
13% less funds holding
Funds holding: 161 [Q4 2024] → 140 (-21) [Q1 2025]
29% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 38
56% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 27
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Goldman Sachs Paul Choi 56% 1-year accuracy 9 / 16 met price target | 34%downside $7 | Sell Maintained | 17 Apr 2025 |
Financial journalist opinion
Based on 4 articles about AMRN published over the past 30 days








![New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo](https://wsr-news.imgdelivr.io/8XNJYGFA.jpg?w=640&h=360)
